LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
NEW YORK, Nov. 14, 2016 -- Scott+Scott, Attorneys at Law, LLP (“Scott+Scott”) has filed an action in the United States District Court – Western District of Kentucky against Humana, Inc. and Humana Pharmacy Solutions, Inc. (collectively, “Humana” or “Defendants”).
Defendants are health insurance companies along with pharmacy benefit managers (“PBMs”). The PBMs are retained by the health insurance companies, on behalf of the plan or third-party payors, to provide the pharmacy benefits to plan members, which includes, inter alia, establishing a formulary of drugs that will be covered, a network of pharmacies that will serve as participating pharmacies for plan participants to obtain their prescriptions, copayment amounts, coinsurance amounts, and deductibles.
Specifically, the action relates to Defendants engaging in a scheme to defraud plan members by artificially inflating the copayment of medically necessary prescription drugs well above the cost of the drug. Plan participants, including Plaintiff and the Class, pay inflated copayments to participating pharmacies in exchange for receiving their prescription drugs. Unbeknownst to the plan participants, Defendants artificially inflate the purported costs of the prescription drugs in the form of increased copayments and then “claw back,” or recoup, from the pharmacies a large portion of the copayments.
Class members are consumers who pay artificially inflated copayments for medically necessary, covered prescriptions that cost plan participants more than if they did not have insurance. If you would like addition information, please contact Michael Burnett of Scott+Scott ([email protected], (800) 404-7770, (860) 537-5537).
About Scott+Scott, Attorneys at Law, LLP
Scott+Scott has significant experience in prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide.
CONTACT: Michael Burnett Scott+Scott, Attorneys at Law, LLP (800) 404-7770 [email protected]
